736 related articles for article (PubMed ID: 24387680)
1. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients.
Zhang Y; Li J; Lou J; Zhou Y; Bo L; Zhu J; Zhu K; Wan X; Cai Z; Deng X
Crit Care; 2011; 15(1):R70. PubMed ID: 21349174
[TBL] [Abstract][Full Text] [Related]
3. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
Chang KC; Burnham CA; Compton SM; Rasche DP; Mazuski RJ; McDonough JS; Unsinger J; Korman AJ; Green JM; Hotchkiss RS
Crit Care; 2013 May; 17(3):R85. PubMed ID: 23663657
[TBL] [Abstract][Full Text] [Related]
5. Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration.
Thampy LK; Remy KE; Walton AH; Hong Z; Liu K; Liu R; Yi V; Burnham CD; Hotchkiss RS
PLoS One; 2018; 13(6):e0199497. PubMed ID: 29944697
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.
Li W; Tu J; Liu X; Yang W
Clin Exp Immunol; 2017 Oct; 190(1):8-18. PubMed ID: 28556912
[TBL] [Abstract][Full Text] [Related]
7. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
[TBL] [Abstract][Full Text] [Related]
8. [Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction].
Li Z; Zhao D; Zhou X; Tang L
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):357-361. PubMed ID: 35692198
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
Wilson JK; Zhao Y; Singer M; Spencer J; Shankar-Hari M
Crit Care; 2018 Apr; 22(1):95. PubMed ID: 29661225
[TBL] [Abstract][Full Text] [Related]
10. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.
Zhang Y; Zhou Y; Lou J; Li J; Bo L; Zhu K; Wan X; Deng X; Cai Z
Crit Care; 2010; 14(6):R220. PubMed ID: 21118528
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma increases monocyte PD-L1 but does not diminish T-cell activation.
Galbraith NJ; Walker SP; Gardner SA; Bishop C; Galandiuk S; Polk HC
Cell Immunol; 2020 Nov; 357():104197. PubMed ID: 32891037
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
15. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
16. Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.
Goto S; Konnai S; Okagawa T; Nishimori A; Maekawa N; Gondaira S; Higuchi H; Koiwa M; Tajima M; Kohara J; Ogasawara S; Kato Y; Suzuki Y; Murata S; Ohashi K
Immun Inflamm Dis; 2017 Sep; 5(3):355-363. PubMed ID: 28544524
[TBL] [Abstract][Full Text] [Related]
17. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
18. Glutamine Administration in Early or Late Septic Phase Downregulates Lymphocyte PD-1/PD-L1 Expression and the Inflammatory Response in Mice With Polymicrobial Sepsis.
Hu YM; Hsiung YC; Pai MH; Yeh SL
JPEN J Parenter Enteral Nutr; 2018 Mar; 42(3):538-549. PubMed ID: 28633555
[TBL] [Abstract][Full Text] [Related]
19. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M; Abnous K; Rafatpanah H; Ramezani M
J Recept Signal Transduct Res; 2018 Feb; 38(1):31-36. PubMed ID: 29252078
[TBL] [Abstract][Full Text] [Related]
20. Human CD8
Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
Front Immunol; 2018; 9():2788. PubMed ID: 30555473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
